These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 27539844)

  • 1. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
    D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
    J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
    Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
    Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.
    Viola-Villegas NT; Sevak KK; Carlin SD; Doran MG; Evans HW; Bartlett DW; Wu AM; Lewis JS
    Mol Pharm; 2014 Nov; 11(11):3965-73. PubMed ID: 24779727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerenkov luminescence imaging of medical isotopes.
    Ruggiero A; Holland JP; Lewis JS; Grimm J
    J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen.
    Elsässer-Beile U; Reischl G; Wiehr S; Bühler P; Wolf P; Alt K; Shively J; Judenhofer MS; Machulla HJ; Pichler BJ
    J Nucl Med; 2009 Apr; 50(4):606-11. PubMed ID: 19289418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
    Timmermand OV; Tran TA; Strand SE; Axelsson J
    J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.
    Maier FC; Schmitt J; Maurer A; Ehrlichmann W; Reischl G; Nikolaou K; Handgretinger R; Pichler BJ; Thaiss WM
    Oncotarget; 2016 Oct; 7(41):67403-67411. PubMed ID: 27602580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes.
    Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W
    J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor.
    Smith-Jones PM; Vallabhajosula S; Navarro V; Bastidas D; Goldsmith SJ; Bander NH
    J Nucl Med; 2003 Apr; 44(4):610-7. PubMed ID: 12679407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
    Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
    J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation of
    Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K
    J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.
    Nedrow JR; Latoche JD; Day KE; Modi J; Ganguly T; Zeng D; Kurland BF; Berkman CE; Anderson CJ
    Mol Imaging Biol; 2016 Jun; 18(3):402-10. PubMed ID: 26552656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and Preclinical Evaluation of an Albumin-Binding PSMA Ligand for
    Umbricht CA; Benešová M; Hasler R; Schibli R; van der Meulen NP; Müller C
    Mol Pharm; 2018 Dec; 15(12):5556-5564. PubMed ID: 30376344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging.
    Xu Y; Chang E; Liu H; Jiang H; Gambhir SS; Cheng Z
    J Nucl Med; 2012 Feb; 53(2):312-317. PubMed ID: 22241909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraoperative
    Darr C; Harke NN; Radtke JP; Yirga L; Kesch C; Grootendorst MR; Fendler WP; Costa PF; Rischpler C; Praus C; Haubold J; Reis H; Hager T; Herrmann K; Binse I; Hadaschik B
    J Nucl Med; 2020 Oct; 61(10):1500-1506. PubMed ID: 32060212
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Costa PF; Püllen L; Kesch C; Krafft U; Tschirdewahn S; Moraitis A; Radtke JP; Ting S; Nader M; Wosniack J; Kersting D; Lückerath K; Herrmann K; Fendler WP; Hadaschik BA; Darr C
    J Nucl Med; 2023 Apr; 64(4):598-604. PubMed ID: 36357181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody.
    Wiehr S; Bühler P; Gierschner D; Wolf P; Rolle AM; Kesenheimer C; Pichler BJ; Elsässer-Beile U
    Prostate; 2014 May; 74(7):743-55. PubMed ID: 24610028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multimodal imaging with (18)F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model.
    Robertson R; Germanos MS; Manfredi MG; Smith PG; Silva MD
    J Nucl Med; 2011 Nov; 52(11):1764-9. PubMed ID: 21994410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors.
    Gourni E; Canovas C; Goncalves V; Denat F; Meyer PT; Maecke HR
    PLoS One; 2015; 10(12):e0145755. PubMed ID: 26700033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions.
    Holland JP; Normand G; Ruggiero A; Lewis JS; Grimm J
    Mol Imaging; 2011 Jun; 10(3):177-86, 1-3. PubMed ID: 21496448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.